oral therapy
- Business Wire
Takeda Announces U.S. FDA Grants Priority Review for New Drug Application for Mobocertinib (TAK-788) as a Treatment for EGFR Exon20 Insertion+ Metastatic Non-Small Cell Lung Cancer
− Prescription Drug User Fee Act (PDUFA) Target Action Date Set for October 26, 2021 CAMBRIDGE, Mass. & OSAKA, Japan–(BUSINESS…
Read More » - Business Wire
Merck Announces New Data Strengthening Evidence for Continued Safe and Effective MAVENCLAD® Use During the COVID-19 Pandemic
New analysis indicates a specific immune repopulation pattern in people treated with MAVENCLAD, which may contribute to their ability to…
Read More »